Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel
NASDAQ:STTK

Shattuck Labs Q4 2024 Earnings Report

Shattuck Labs logo
$4.63 -0.31 (-6.28%)
Closing price 06/15/2026 04:00 PM Eastern
Extended Trading
$4.78 +0.15 (+3.24%)
As of 06:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Shattuck Labs EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.38
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Shattuck Labs Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Shattuck Labs Announcement Details

Quarter
Q4 2024
Date
3/27/2025
Time
Before Market Opens
Conference Call Date
Wednesday, March 26, 2025
Conference Call Time
7:00PM ET

Upcoming Earnings

Shattuck Labs' Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 10, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Shattuck Labs' Q4 2024 Press ReleasePress Release
(8-K)
Shattuck Labs' Q4 2024 Annual reportAnnual report
(10-K)

Shattuck Labs Earnings Headlines

Shattuck Labs (NASDAQ:STTK) Upgraded at Wall Street Zen
June 13 at 1:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30835880
Shattuck Labs Prices Upsized Public Equity and Warrant Offering
June 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/shattuck-labs-prices-upsized-public-equity-and-warrant-offering?utm_source=marketbeat.com&utm_medium=referral
This Could Be the Biggest Monetary Shift in 50 Years
Tucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold reserves from $42 per ounce to today's market value - a potential 107x shift. President Trump has signaled interest in returning the dollar to commodity-backed foundations. More than 60 million Americans can move a portion of their savings into physical gold, tax-free and penalty-free, before any policy change is announced. The 2026 Gold Guide explains exactly how to position your 401(k) or IRA outside the dollar-denominated system.tc pixel
June 16 at 1:00 AM  |  Americas Gold Company (Ad)
Shattuck Labs: "Hold" On Phase 1 SL-325 Data And Next Stage Of Development
June 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4913656-shattuck-labs-hold-on-phase-1-sl-325-data-and-next-stage-of-development
Shattuck Labs drops 6%, prices $75M share raise at $4 per share
June 10, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/shattuck-labs-drops-6-prices-75m-share-raise-at-4-per-share/ar-AA25h2ry
What's going on with Shattuck Labs stock Wednesday?
June 10, 2026  |  msn.comhttps://www.msn.com/en-us/money/news/what-s-going-on-with-shattuck-labs-stock-wednesday/ar-AA25iChv
See More Shattuck Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shattuck Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shattuck Labs and other key companies, straight to your email.

About Shattuck Labs

Shattuck Labs (NASDAQ:STTK) (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities. Preclinical studies have demonstrated that vaccinated animals produce robust anti‐fentanyl antibody titers and are protected against lethal and sublethal fentanyl challenges. Shattuck Labs is advancing its vaccine candidate through IND‐enabling studies and plans to initiate first‐in‐human trials to evaluate safety, immunogenicity, and its potential to block the psychoactive effects of fentanyl.

Founded in 2017, Shattuck Labs was established to address the growing public health crisis posed by opioid misuse and overdose. The company leverages insights from immunology and vaccinology, collaborating with academic partners and contract manufacturing organizations to streamline development and scale up production. Shattuck Labs serves the U.S. market and is preparing for broader geographic reach as its clinical programs progress.

Shattuck Labs is led by Chief Executive Officer Craig H. Wheeler, who brings extensive experience in biopharmaceutical R&D and commercial strategy. The management team includes experts in vaccine formulation, regulatory affairs, and translational medicine. Through its focused pipeline and innovative platform, Shattuck Labs aims to pioneer a new class of non‐addictive, immunotherapeutic treatments for substance use disorders.

View Shattuck Labs Profile
Earnings Tools